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Even though attempts have been effectively applied to eradicate the neonatal tetanus through 
widespread childhood vaccination and improved conditions at delivery, it remains major cause of 
infant mortality and continues a problem of public health in developing countries including Yemen.  
The aims of this study were to determine the tetanus immunization status, the association between the 
risk factors and failure of protection in pregnant women at time of delivery. This cross-sectional study 
included 476 women seeking care for delivery at Al Thawra Modern General Hospital and Al Sabain 
Hospital, women age ranged from 16-49 years old. Immunization information and factors effecting it 
were obtained through a standard questionnaire. Serum samples were collected and level of IgG 
antibody against Clostridium tetani was measured by ELISA technique. Protected women were defined 
as those with serum antibody levels > or = 0.6 IU/ml.  The total vaccine covering rate of tetanus was 
87%, and  maternal vaccine rate was 33.6%, the protective rate at time of delivery was 68.5%. There 
were significant association between  unvaccinated (OR=18.6), older ages (OR=1.7), rural residency 
(OR=34) and malaria infection during pregnancy (OR=2.9); with protection failure in pregnant women 
at time of delivery. It can be concluded that the total vaccine coverage rate and antenatal tetanus 
vaccine rate were insufficient. In addition, the protective rate at time of delivery was low and large 
numbers of neonate are susceptible to neonatal tetanus and death. Vaccinating every pregnant woman 
with at least one dose of TT would be an affordable and effective way to protect against neonatal 
tetanus, and would be a step toward eliminating the deaths that continue to occur due to this 
preventable disease in Yemen. 




  Tetanus is an acute infection, non-communicable disease with a high case fatality rate, caused by 
Clostridium tetani (C. tetani)
1
. Tetanus is a disease resulting from a specific toxin produced at site of 
injury by the anaerobic, spore forming organism C. tetani which is finding in soil and feces. Tetanus 
has been a major cause of death worldwide, largely due to inadequate vaccination and poor wound 
prophylaxis
2
. During sporulation the vegetative form of the organism develops into a spore form, 
giving a characteristic drumsticks appearance in blood smear. The spores of this organism are very 
resistant to disinfectants. Also, the spore form can survive for many years in soil
 3,4
. Tetanus can affect 
all age groups but umbilical card infection during delivery is the most common form affecting newborn 
babies and mothers, case mortality of tetanus can be 100% if untreated and can range between 10-60% 
even under hospitalized care. There is no natural immunity against tetanus 
5
. A significant number of 
women die every year due to maternal tetanus, most of these deaths occur in Africa, East and southern 
Asia
 1
. The global incidence of tetanus has been estimated at approximately one million cases 
annually
6
.  The World Health Organization
5
 reported that globally 49.000 newborns died of this disease 
in 2013 alone. Tetanus kills one newborn every eleven minute, approximately 134 babies every day
1
. 
Eradication of tetanus is difficult due to the abundance of tetanus bacterial spores in the environment; 
the goal is to work towards elimination of tetanus through vaccination 
7
.  Neonatal tetanus is a 
  
significant health problem in Yemen. Newborns can be successfully protected against tetanus by 
vaccinating women with tetanus toxoid, the coverage rate of vaccination with this vaccine proved to be 
affected by knowledge, attitude and practice of women about antenatal tetanus toxoid vaccine 
8
. The 
World Health Organization aimed to achieve worldwide neonatal tetanus elimination by 2005, which 
was defined as the reduction of neonatal tetanus cases to less than 1 case per 1,000 live births in every 
district of every country 
9,10
. However, high prevalence remained present in 21 countries including 
Yemen
11
. There is no recent study in Yemen that determines the vaccine coverage rate and the antibody 
level of tetanus at time of delivery. So, this study aimed to determine; vaccine coverage rate and the 
immunological status of tetanus among pregnant women at the time of delivery and factors associated 
of protection failure against tetanus. 
Subjects and Methods 
      This cross-sectional study was carried out during a period of 12 months, starting in August 2017 and 
ending in August 2018.  included 476 women seeking care for delivery at Al Thawra Modern General 
Hospital and Al Sabain Hospital, Sana’a city- Yemen. The study included women at time of delivery, 
and excluded pregnant women before time of delivery and pregnant women who are not sure about 
history of taking the tetanus vaccine.  Serum samples were collected and measured for the level of  IgG 
antibody against Clostridium tetani toxoid by commercially available ELISA technique (Roche). 
Protected women were defined as those with serum antibody levels > or = 0.6 IU/ml. A full history was 
taken from each studied individual; and the findings were recorded in a predesigned questionnaire in 
which data collection was based on face to face interviews.. The data collected included demographic 
data,  number of deliveries, number of abortions, body weight, mother’s knowledge about tetanus, and 
history of mother's tetanus vaccine and factors that might effect on immune response of  women at time 
of delivery.  
Statistical Analysis 
To relate possible risk factors of vaccine failure for tetanus, the data were examined in a case-control 
study format. For women with evidence of vaccine failure (serum antibody levels < 0.6 IU/ml)  were 
matched up with those who were Protected ( serum antibody levels > or = 0.6 IU/ml).  
Ethical Consideration 
Ethical clearance for the study was taken from the Faculty of Medicine and Health Sciences Research 
Review Committee. Informed Consent was taken from the volunteers before the collecting specimens. 
RESULTS 
Table 1 shows the IgG antibody levels and the rates of protection and non-protection against tetanus 
among studied pregnant women at time of delivery. the protective rate at time of delivery was 68.5%, 
while 31.5% were not protected.  Table 2 shows the association between age groups and non-protection 
rate against tetanus among studied pregnant women. There were significant association between  older 
age and failure of protection in which the rate of failure in the older age group 36-49 years was 41.3% 
with odds ratio (OR) equal to 1.9, 95% CI= 1.1-3.2, χ2= 6.4, p=0.01, while the rate of failure was lower 
in other younger age groups.  Table 3 shows vaccine coverage rates and factors associated with 
protection failure against tetanus among pregnant women at time of delivery. The total vaccine 
covering rate of tetanus was 87%, and maternal vaccine rate (antenatal tetanus vaccine) was 33.6%, 
  
also the childhood vaccine coverage was very low (0.3%), and school-age coverage rate was 40.9%. 
When factors of non-protection were considered, there were significant association between  history of 
un-vaccinated women and non-protection against neonatal tetanus (NT)  with protection failure rate 
equal to 85% and OR equal to 18.6, 95% CI= 8 -39, χ2= 93, <0.001, rural residency with failure rate 
equal to 59% and OR equal to 34, 95% CI= 1.8 -6.5, χ2= 16.2, <0.001; and malaria infection during 
pregnancy with failure rate equal to 59% and OR equal to 34, 95% CI= 1.8 -6.5, χ2= 16.2, <0.001.   
Discussion 
Fetuses have acquired passive immunity against tetanus if their mothers are adequately 
immunized, two or more doses of tetanus toxoid vaccine to the mother have been shown to reduce NT 
mortality by 94% 
12
. The WHO recommends a primary series of three doses of DTP vaccine in the first 
year of life and three booster doses of tetanus toxoid in later childhood, and adulthood to prevent 
tetanus in all ages. The target date for global maternal neonatal tetanus elimination (MNTE) was 2015. 
But in August 2015, elimination had not been achieved in 21 countries including Yemen 
11
. This study 
indicated that the rate of overly protection with IgG antibody level (≥0.6 IU/ml) was 68.5% among the 
studied pregnant women at time of delivery in Sana’a city, Yemen. This result is similar to that 
reported in Turkey where the rate of protective pregnant women was 69.0% with serum antibody level 
(≥0.6 IU/ml) 13. In contrast, the present result is in disagreement with previous studies where the 
protection rates were as follow: in Yemen (87.70%) 
14
, in Iraq (90%) 
15
 and in India (94%) 
16
. This low 
rate in our study could be due to that most mothers received only 1 and/or 2 doses of tetanus vaccine 
which leaded to failure protection of mothers to produce an adequate immune response at time of 
delivery. Also booster doses of TT are not routinely given in Yemeni family medical practice except in 
cases of serious injury.   In this study, there statistical significant association between the failure of 
protection and older age group (p >0.05).The same results were found in Iraq (p<0.05)
15
, in Combodia 
(p<0.001) 
11
, and in Taiwan where the level of anti-tetanus antibodies were decline with age from  
4.8IU/ml in those aged 16-19 and to 0.82-0.87 IU/ml in those aged >51years (p=0.001)
11
.  However, 
this study was in disagreement with other studies conducted in Turkey (p>0.05) 
13
 and in Indonesia 
(p>0.05) 
17
 in which no effect of age in the rate of protection failure. The present study indicated 
statistical significant association between residence in rural areas and failure of protection among 
studied pregnant women (p<0.001), which disagreed with previous studies as follows: in Yemen 
(p=0.96) 
14
, in Turkey (p>0.05) 
13
, in Cambodia (p=0.88) 
11
 and in Senegal (p=0.067) 
18
 in which no 
difference in the rate of failure between rural and urban areas. This indicated that the vaccine program 
covered urban more than rural areas in Yemen.  In the current study the total vaccine covering rate of 
tetanus was 87%, and maternal vaccine rate (antenatal tetanus vaccine) was 33.6%, only also the 
childhood vaccine coverage was very low (0.3%), and school-age coverage rate was 40.9%. which 
disagreed with previous studies in Turkey 
13
, in Cambodia  
11
 and in Senegal
18
 in which vaccine 
covering rate of tetanus, maternal vaccine rate, childhood vaccine  coverage rate and school-age 
coverage rate were above 90%. Our low rates could be due to the lack of vaccine register data base and 
therefore the vaccination history obtained verbally from the women may be unreliable. Also, it could 
be due to of the incorrect idea about vaccine contraindication with pregnancy as some women believe 
that taking the vaccine during pregnancy could cause abortion. 
The current study found a significant association between un-vaccination  with failure of 
protection in which the protection failure rate was 85% with OR=18.6 (p<0.001). This result is similar 
to previous studies conducted in India (p<0.05) 
16
 and in Vietnam (p<0.05) 
19
. However, this result is in 
  
disagreement with a study conducted in Portugal where the difference in antibody concentration (for 
both pre and post-vaccination) between those two groups were not statistically significant
20
.This 
difference may be due to the global status of serological immunity against tetanus varies between 
countries as a result of different national vaccination policies and the criteria used for determination of 
serum levels of tetanus antitoxin.   The present study, found  signification association between lower 
rate of protection failure and taking the vaccine during pregnancy (p<0.001). This result is in 
agreement with a previous study which indicated that when women take the vaccine during pregnancy 
this would provide the highest concentration of maternal antibodies to be transferred to their fetuses
21
.   
In this study, a statistical significant association between taking the last dose of tetanus vaccine and low 
failure rate of protection was found (14.8%) p=0.041). This result  agreed with previous studies in other 
countries where the failure protection rates were as follow: in Iraq (8%), 
15
, and  in Tanzania (5.1%) 
22
. 
The current study found statistical significant association between the malaria infection and failure of 
protection (57%, p<0.001). This result is in agreement with studies  reported in Gambia 
23
, and in 
Kenya
24
. This result can be explained by the findings of Cumberland et al
25
 in which mother infected 
with malaria had reduce level of antibodies in spite of vaccination also they found that placental 
malaria reduce transfer of antibody to fetus 
25
. This result reflects the negative effect of malaria in 
immune system particularly in humeral immunity. 
Conclusion 
In conclusion, the total vaccine covering rate and antenatal tetanus vaccine rate were insufficient. In 
addition, the protective rate at time of delivery was low and large numbers of neonate are susceptible to 
neonatal tetanus and death. Vaccinating every pregnant woman with at least one dose of TT would be 
an affordable and effective way to protect against neonatal tetanus, and would be a step toward 
eliminating the deaths that continue to occur due to this preventable disease in Yemen. 
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Table 1: The IgG antibody levels and the rates of protection and non-protection against tetanus among 
studied pregnant women at time of delivery in Sana’a city, 2018 
 
IgG Antibody Levels in IU/ ml No. %  P  Interpretation 
 









Susceptible for neonatal tetanus 
 






Protective for neonatal tetanus 
total 476 100   
 
Table 2: The association between age groups and non-protection against tetanus among studied 




OR CI χ2 P 
No. % 
16-25 
n=234 72 30.7 0.88 0.0-1.3 0.39 0.53 
26-35 
n=167 45 26.9 0.71 0.4 -1.08 2.4 0.11 
36-49  
n=75 33 44 1.9 1.1-3.2 6.4 0.011 
Total=476 
150 31.5     
 
OR   Odds ratio >1 (at risk) 
CI    Confidence intervals 95%   
χ2     Chi-square 03.9 (significant) 
p     Probability value <0.05 (significant) 
  
Table 3: Vaccine coverage and factors associated with protection failure against tetanus among 










Infancy (3DPT) n= 373 373/476 
78.4% 76 20.4 0.04 0.02-0.07 151 <0.001 
Childhood 1 dose n=30 30/476 
6.3% 4 13.3 0.3 0.1-0.89 5.1 0.02 
School age 1 dose 
N=195 
195/476 
40.9% 35 17.9 0.2 0.19-0.46 30.8 <0.001 
Vaccination during pregnancy 
 




33.6% 19 11.9 0.18 0.1-0.3 45 <0.001 
One dose n=27 27/476 
5.7% 4 14.8 0.3 0.1-1 3.9 0.047 
*MALARIA n=14 14/14 
100% 8 57.1 2.9 1.0-8.5 4.1 0.041 
Total vaccinated n=414 414/476 
87% 97 23.4 0.0 undefined 126 <0.001 
Total unvaccinated n=62 62/476 
13% 53 85 18.6 8.8-39 93 <0.001 
Residency 
Urban n=432 392/432 
90.7% 124 28.7 0.13 0.06-0.3 30 <0.001 
Rural n=44 22/44 
50% 26 59 34 1.8-6.5 16.2 <0.001 
 
*All vaccinated at 27 and 36 gestation dose  
 
OR   Odds ratio >1 (at risk) 
CI    Confidence intervals 95%   
χ2     Chi-square 03.9 (significant) 
p     Probability value <0.05 (significant) 
 
